Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344999 | 0.83 | CYP1A2 (0.39) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL23995664 | 0.79 | ALDH1A1 (0.37) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL23345013 | 0.77 | HPGD (0.44) | MAPK1TSHRALDH1A1 | |
| SCHEMBL23345000 | 0.77 | ALDH1A1 (0.49) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL23345230 | 0.76 | CYP4F2 (0.40) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL15451913 | 0.74 | CYP1A2 (0.53) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL31143203 | 0.73 | CYP3A4 (0.49) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL3632294 | 0.72 | CYP1A2 (0.56) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL8603867 | 0.72 | — | — | |
| SCHEMBL20617537 | 0.72 | L3MBTL1 (0.53) | CYP2C9USP2CYP1A2CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | CYP2C9 2750/4885USP2 3363/4885CYP1A2 1997/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | CYP2C9 3034/4885USP2 2941/4885CYP1A2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.